Enliven Therapeutics Inc. (ELVN)
20.42
-1.65 (-7.48%)
At close: Jan 14, 2025, 3:59 PM
21.40
4.80%
Pre-market Jan 15, 2025, 04:11 AM EST
undefined% (undefined)
| Bid | 8.19 |
| Market Cap | 997.70M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.89 |
| PE Ratio (ttm) | -10.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 21.37 |
| Volume | 465,459 |
| Avg. Volume (20D) | 212,783 |
| Open | 22.18 |
| Previous Close | 22.07 |
| Day's Range | 20.16 - 22.57 |
| 52-Week Range | 10.90 - 30.03 |
| Beta | undefined |
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2020
Employees 46
Stock Exchange NASDAQ
Ticker Symbol ELVN
Analyst Forecast
According to 5 analyst ratings, the average rating for ELVN stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 81.19% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+6.02%
Enliven Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
9 months ago ·
Source
+20.18%
Enliven Therapeutics shares are trading higher after the company announced proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.
